Psyched Wellness Ltd · CSE:PSYC
Psyched Wellness — Investor Presentation (March 2022)
18 slides from Psyched Wellness's investor presentation, March 2022
Slide 1: Corporate Deck
Corporate Deck CSE:PSYC OTCQB:PSYCF FRANKFURT:5U9
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This document and the material contained herein are confidential and are not to be disclosed to the public. This is for information purposes only and may not be reproduced or distributed to any other person or published, in whole or part, for any purpose whatsoever. Certai
Slide 3: At a glance
At a glance Psyched Wellness Ltd. is a Canadian-based Life Sciences company focused on the research and development of a legal psychedelic mushroom called Amanita Muscaria. Psyched Wellness is led by a strong team including experts in all key streams for an R&D public company and is currently engage
Slide 4: Launching the first legal Amanita Muscaria mushroom product in North America
We are launching the first legal Amanita Muscaria mushroom product in North America. “Calm” is the only AME-1 product approved for sale as a food supplement, in the USA. It is designed to help you get the rest you need. The over-the-counter sleep category continues to grow. Calm has been investigate
Slide 5: Uncapped Retailer Landscape
Uncapped Retailer Landscape Unlike Psilocybin or Cannabis, our Amanita Muscaria Tincture with AME-1 will be available for sale at traditional retailers, without a prescription. This means Psyched Wellness has the potential to sell our products to hundreds of thousands of relevant retail locations. W
Slide 6: Next Up
Next Up First, we establish our routes-to- market and retailer landscape…then we expand assortment “Calm” is the first of a diverse portfolio of product applications. Alongside our phenomenal CMO partner we are readying skus in the capsule and tea verticals. Additionally, we are investigating releva
Slide 7: White and Private Labelling Opportunities
White and Private Labelling Opportunities White labeling allows you to offer Amanita Muscaria products to your consumers with your branding. There’s more! AME-1 bulk wholesale empowering partner orgs while also building Psyched revenue + additional awareness of the Amanita Muscaria mushroom. Psyched
Slide 8: Investment Highlights
Investment Highlights: 1. First mover advantage as the only public 2. Expedited path to market/revenue as a food company studying Amanita Muscaria supplement via a GRAS and Health Canada (a Natural Health Product Number) 4. Global market opportunity as Amanita 3. Management supported by top tier boa
Slide 9: Management Team
Management Team: Jeff Stevens David Shisel Matthew Singh Keith Li CEO & DIRECTOR COO CCO CFO Mr. Stevens has 20+ years of Mr. Shisel is an entrepreneur Mr. Singh is a seasoned Consumer Mr. Li is a CPA, CA with 10+ capital markets experience specializing in the medical Packaged Goods (CPG) executive
Slide 10: About Amanita Muscaria
About Amanita Muscaria: Iconic mushroom Ancient use Unique compounds Not poisonous Amanita Muscaria typifies the Amanita Muscaria has been The major compounds, ibotenic This mushroom has been iconic image of psychogenic and consumed by cultures worldwide acid and muscimol, are water- mislabelled as
Slide 11: Achievements
Achievements Psyched Wellness will finalize its R&D process and will start sales of its first flagship Amanita Muscaria tincture in the USA via a GRAS certification and will apply to sell in Canada as a Natural Health Product (NHP). This will be the first psychedelic food supplement that is to be sold w
Slide 12: Product Development & Marketing Rollout
Product Development & Marketing Rollout Q1 2022 Q2 2022 Q3 2022 Q4 2022 • Submit the application for the AME-1 • Launch a new website (desktop and mobile) • GRAS approval for the USA • Commence R&D on Psyched Wellness’s as a NHP to Health Canada • Submit a GRAS application for the AME-1 in Host a di
Slide 13: 2022 Action Plan
2022 Action Plan • Psyched Wellness will finalize its R&D process and will start sales of its first flagship Amanita Muscaria tincture in the USA via a GRAS designation and will apply to sell it in Canada as a Natural Health Product (NHP). • This will be the first psychedelic food supplement that is
Slide 14: Capital Structure
Capital Structure Currently Issued and Outstanding Common Shares* 135,514,695 Finders Warrants 23,886,365 Options 12,875,000 Fully Diluted Issued and Outstanding 172,276,060
Slide 15: Board of Directors
Board of Directors Michael Nederhoff Terry Booth Professor David Nutt CHAIRMAN DIRECTOR DIRECTOR David Nutt is a psychiatrist and the Edmond J. Currently acts as President of JUUL Labs in Global cannabis industry pioneer and Safra Professor of Neuropsychopharmacology in Canada overseeing Canadian op
Slide 16: Board of Directors (cont'd)
Board of Directors (cont'd) Nick Kadysh Janeen Stodulski Amanda Galbraith DIRECTOR DIRECTOR DIRECTOR Head of Corporate Affairs at UUL MA graduate of Brock University, Janeen received her CPA Amanda Galbraith is one of Canada’s foremost crisis Labs Canada. Formerly served as designation in 1999 and h
Slide 17: Advisory Board
Advisory Board Dr. Dawn DeCunha Dr. Andrew Kohler Brian Tancowny ADVISOR ADVISOR ADVISOR Dr. Dawn DeCunha is a clinical psychologist, with Dr. Kohler is the founder and owner of Callingwood Mr. Brian Tancowny has over 25 years of experience in an active practice in Toronto, Canada. She is a Crossing
Slide 18: Contact
Contact Address 77 King St West Toronto, ON, Canada M5K 1G8 Jeff Stevens CEO & Director jstevens@psyched-wellness.com (647) 400-8494
Psyched Wellness — Investor Presentation (March 2022) on 6ix